Cyclerion Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $6.9M
- Website
- http://www.cyclerion.com
- Introduction
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was fo...
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-07-15
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03892499
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03818295
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT03795519
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc., Madison, Wisconsin, United States
A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers
- First Posted Date
- 2018-04-17
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03499106
- Locations
- 🇺🇸
IQVIA, Overland Park, Kansas, United States
A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 88
- Registration Number
- NCT03285178
- Locations
- 🇱🇧
Hammoud Hospital University Medical Center, Sidon, Lebanon
🇺🇸Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 26
- Registration Number
- NCT03091920
- Locations
- 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 9
- Registration Number
- NCT02931565
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Utah School of Medicine, Division of Gastroenterology, Hepatology & Nutrition, Salt Lake City, Utah, United States
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 11
- Registration Number
- NCT02906579
- Locations
- 🇺🇸
ICON Early Phase Unit, San Antonio, Texas, United States
A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 67
- Registration Number
- NCT02792998
- Locations
- 🇺🇸
ICON Early Phase Unit, San Antonio, Texas, United States
Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2019-04-03
- Lead Sponsor
- Cyclerion Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT02616861
- Locations
- 🇺🇸
Ironwood Investigator, San Antonio, Texas, United States